Gilead Sciences, Inc. (GILD)
| Market Cap | 80.53B |
| Revenue (ttm) | 27.45B |
| Net Income (ttm) | 484.00M |
| Shares Out | 1.25B |
| EPS (ttm) | 0.35 |
| PE Ratio | 184.51 |
| Forward PE | 8.68 |
| Dividend | $3.08 (4.77%) |
| Ex-Dividend Date | Jun 14, 2024 |
| Volume | 6,021,471 |
| Open | 65.18 |
| Previous Close | 64.92 |
| Day's Range | 64.52 - 65.22 |
| 52-Week Range | 64.33 - 87.87 |
| Beta | 0.24 |
| Analysts | Buy |
| Price Target | 84.27 (+30.49%) |
| Earnings Date | Apr 25, 2024 |
About GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2023, GILD's revenue was $27.12 billion, a decrease of -0.60% compared to the previous year's $27.28 billion. Earnings were $5.67 billion, an increase of 23.37%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for GILD stock is "Buy." The 12-month stock price forecast is $84.27, which is an increase of 30.49% from the latest price.
News
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
REDWOOD CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered...
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
REDWOOD CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered...
Will Gilead Sciences Stock Recover To Its Pre-Inflation Shock Highs Of Around $75?
Gilead Sciences stock (NASDAQ NASDAQ : GILD) trades at $65 per share, about 11% below the level seen in December 2021. GILD stock was trading at around $62 in early June 2022, just before the Fed star...
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 18 abstracts during the 2024 American Society of Clinical Onc...
MRNA, GILD: What to Watch in Biotech Stocks
Fiscal discipline is important going forward, notes Hartaj Singh on Moderna (MRNA). He discusses biotech stocks Moderna and Gilead Sciences (GILD).
Gilead Sciences to Present at Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Ca...
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the sa...
Gilead Beats Earnings Expectations After Rocky Quarter
The biotech reported a loss for the quarter of $1.32 per share, better than the FactSet consensus estimate of a loss of $1.49 per share.
Gilead's quarterly loss is narrower than expected
Gilead Sciences Inc.'s stock rose 0.8% in after-hours trading Thursday, after the drug company's adjusted first-quarter profit was narrower than expected.
Gilead posts quarterly loss, revenue rises 5%
Gilead Sciences reported a first-quarter loss on Thursday after taking a $3.9 billion charge for its recent acquisition of liver drug developer CymaBay Therapeutics, while revenue rose 5% on higher HI...
Gilead Sciences Announces First Quarter 2024 Financial Results
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations. “Gilead delivered another strong quarter of revenue...
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2024 financial results and guidance will be released on Thursday, April 25...
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) fo...
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
FOSTER CITY, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and com...
Nucleus RadioPharma Announces Appointment of Chris McDonald from Kite, a Gilead Company, to Board of Directors
ROCHESTER, Minn.--(BUSINESS WIRE)--Nucleus RadioPharma, the world's first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the appoi...
Christi Shaw, Former CEO of Kite, a Gilead Company, Appointed to Cellares Advisory Board to Advance Cell Therapy Manufacturing
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, a leader in the automation of cell therapy manufacturing and the world's first Integrated Development and Manufacturing Organization (IDMO), tod...
Gilead Sciences Announces Completion of Acquisition of CymaBay
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) f...
Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant
LAFAYETTE, Colo.--(BUSINESS WIRE)--The Center for Disease Analysis Foundation (CDA Foundation) is thrilled to announce the first-round recipients of the CDAF-Relink grant to connect Hepatitis B and C ...
Gilead CAR-T cancer therapy capacity to quadruple by 2026
Gilead Sciences will be able to quadruple production of its cell therapy cancer treatments by 2026 due to improvements in the U.S. biotech's manufacturing processes, an executive in charge of that bus...
Protesters Keep Heat on Greedy Gilead over Price Gouging
MIAMI--(BUSINESS WIRE)--Protesters Keep Heat on Greedy Gilead over Price Gouging.
AHF Keeps Pressure on ‘Greedy Gilead' Over Price Gouging
MIAMI--(BUSINESS WIRE)--AHF Keeps Pressure on ‘Greedy Gilead' Over Price Gouging.
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) wit...
Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from three studies evaluating the efficacy and safety profile of Biktarvy® (bictegravir 50 mg/emtric...
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
FOSTER CITY, Calif., & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the...